Human in vitro maturation (IVM) is an approach that was developed about 50 years ago, although its use in IVF methods is still limited mainly to oncofertility treatments and female factor infertility, especially in the case of polycystic ovary syndrome (PCOS). IVM can be considered as an additional tool in IVF to mimic physiological oocyte maturation, which corresponds to resumption of the first meiotic division and progression from diplotene to metaphase II (MII). Oocyte maturation is characterized by the disappearance of the germinal vesicle (GV), chromosome condensation, spindle formation and separation of homologous chromosomes, extrusion of the first polar body, and arrest of the meiotic process at MII until fertilization (1). Successful oocyte maturation requires the completion of nuclear maturation through meiosis I and II and the maintenance of a good synchronization with cytoplasmic maturation (2, 3). The key to IVM success goes beyond the identification of the best IVM medium and technical conditions. Therefore, the oocyte, its source, and its follicular environment should be considered as the crucial points. This could offer an acceptable explanation for the currently poor implantation rate and delivery rate per transferred embryos after IVM (about half of the rates obtained after routine IVF) (4), particularly in the case of women with PCOS (5, 6). However, other studies did not find any difference